



#### Hepatitis C Therapy

Sofosbuvir/Velpatasvir (Epclusa™) sbuvir/Velpatasvir/Voxilaprevir (Vosevi™) Ribavirin

### Medication Request Form

Phone: 1-800-788-2949 Fax: 858-790-7100

<u>Instructions</u>: This form is to be used by providers to obtain coverage of Hepatitis C therapy. Please complete this form and fax to MedImpact Healthcare Systems, Inc. at (858) 790-7100. Please provide supplemental documentation (e.g. chart notes, lab reports) of the patient's baseline HCV-RNA level, and any addition documentation that is relevant to the request.

If you have any questions regarding this process, please contact MedImpact's Customer Service at (800) 788-2949.

PATIENT INFORMATION	PRESCRIBER INFORMATION		
Name:	Name:		
ID#:	Specialty:		
Date of Birth:	Prescriber NPI#::		
Baseline HCV-RNA:	Phone: ( ) - Fax: ( )	-	
PHARMACYII	NFORMATION		
Pharmacy Name:	Phone: ( ) - Fax: ( )	-	
REQUESTE	D THERAPY		
Preferred Agents:	Non-Preferred Drug Request:		
☐ Sofosbuvir/Velpatasvir: 1 tablet daily	Drug Name and Dose:		
☐ Vosevi: 1 tablet daily			
☐ Ribavirin:	Clinical Justification:		
Length of Treatment weeks	<u> </u>		
Length of Treatment weeks			
Please list any other Hepatitis C therapy that the patient will use	e in addition to the requested therapy above:		
Please answer the following questions:		Yes	No
1. Does the patient have any of the following conditions? (ch	neck all that apply)		
If yes, please continue to #2, otherwise continue to #3			
☐ Recurrent HCV infection post-liver transplantation	☐ Compensated cirrhosis		
HIV coinfection	☐ Decompensated cirrhosis		
☐ Renal impairment (GFR < 30mL/min/1.73m²)	☐ HIV coinfection		
☐ End state renal disease requiring dialysis	<ul><li>☐ HCV in pregnancy</li><li>☐ HCV in children</li></ul>		
☐ Kidney transplant recipient			
☐ HCV-uninfected transplant recipient receiving organifrom HCV-viremic donors	S		
Please provide the patient's HCV genotype (and if available)	e the fibrosis score), then continue to #3		
2. The see provide the patient strey genotype (and it available	the hards score, then continue to no.		
HCV Genotype:			

**CONTINUE ON NEXT PAGE** 



# Medimpact

### **Hepatitis C Therapy**

Sofosbuvir/Velpatasvir (Epclusa™) sbuvir/Velpatasvir/Voxilaprevir (Vosevi™) Ribavirin

## Medication Request Form Phone: 1-800-788-2949 Fax: 858-790-7100

		Yes	No
3.	Does the patient have a limited life expectancy (less than 12 months) due to non-liver-related conditions OR liver related conditions that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy?		
4.	Does the patient have a short life expectancy due to a liver disease?		
5.	Has the patient been evaluated for readiness to initiate treatment? If so, is the patient able and willing to strictly adherence to the treatment protocols prescribed?		
6.	Has the patient been educated regarding potential risks and benefits of Hepatitis C therapy, as well as the potential for resistance and failed therapy if therapy is not taken as prescribed?		
7.	Is the request for an FDA-approved regimen or a regimen recommended by the AASLD? <i>If no, please continue to #8, otherwise continue to #9</i>		
8.	<ul> <li>Investigational request: (Check all that apply)</li> <li>□ Conventional therapy will not adequately treat the intended patient's condition</li> <li>□ Conventional therapy will not prevent progressive disability or premature death</li> <li>□ The provider of the proposed service has a record of safety and success with it equivalent or superior to that of other providers of the investigational service</li> <li>□ The investigational service is the lowest cost item or service that meets the patient's medical needs and is less costly than all conventional alternatives</li> <li>□ The service is not being performed as a part of a research study protocol</li> <li>□ There is a reasonable expectation that the investigational service will significantly prolong the intended patient's life or will maintain or restore a range of physical and social function suited to activities of daily living.</li> <li>□ Requested unlabeled use represents reasonable and current prescribing practices. The determination of reasonable and current prescribing practices shall be based on: 1) reference to current medical literature and 2) consultation with provider organizations, academic and professional specialists.</li> </ul>		
9.	Additional justification:		
	If yes, what was the previously failed therapy?		
10.	Does the patient have a history of treatment failure with prior hepatitis C treatment due to nonadherence with the treatment regimen and appointments?		